As tyrosine kinase receptors, which are ErbB2-like or partners of ErbB2, and some key molecules involving with ErbB2 signaling were reported to be upregulated in trastuzumab-resistant cancer cells [13–17], western blot was used to examine the level of EGFR, HER3, IGF1, AKT and ERK in H2-18-treated NCI-N87 and NCI-N87-TraRT cells. Here, NTRK1 is linked to cancer.